The Manufacturers Life Insurance Company decreased its position in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 81.4% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 254,652 shares of the medical instruments supplier’s stock after selling 1,116,528 shares during the period. The Manufacturers Life Insurance Company owned about 0.09% of Becton, Dickinson and Company worth $38,536,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Larson Financial Group LLC boosted its position in Becton, Dickinson and Company by 1.7% during the 4th quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock valued at $627,000 after buying an additional 53 shares during the period. Atlantic Union Bankshares Corp increased its position in shares of Becton, Dickinson and Company by 0.9% in the fourth quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier’s stock valued at $1,185,000 after acquiring an additional 57 shares during the period. Elevation Point Wealth Partners LLC raised its stake in shares of Becton, Dickinson and Company by 3.7% during the second quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock valued at $256,000 after acquiring an additional 60 shares during the last quarter. BOK Financial Private Wealth Inc. boosted its holdings in shares of Becton, Dickinson and Company by 7.3% during the second quarter. BOK Financial Private Wealth Inc. now owns 1,073 shares of the medical instruments supplier’s stock worth $162,000 after purchasing an additional 73 shares during the period. Finally, Keating Financial Advisory Services Inc. grew its stake in shares of Becton, Dickinson and Company by 41.6% in the second quarter. Keating Financial Advisory Services Inc. now owns 252 shares of the medical instruments supplier’s stock worth $38,000 after purchasing an additional 74 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.
Insider Transactions at Becton, Dickinson and Company
In other news, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the sale, the executive vice president directly owned 13,172 shares of the company’s stock, valued at $1,918,633.52. This represents a 7.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 11,704 shares of company stock valued at $1,963,618 in the last three months. 0.40% of the stock is currently owned by company insiders.
Becton, Dickinson and Company Stock Up 0.2%
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The firm’s revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the company posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.
Becton, Dickinson and Company Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is 126.51%.
Analyst Upgrades and Downgrades
A number of research analysts have commented on BDX shares. UBS Group assumed coverage on Becton, Dickinson and Company in a research report on Tuesday, July 28th. They set a “buy” rating and a $190.00 price target for the company. Royal Bank Of Canada upped their target price on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a report on Thursday, August 13th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. TD Cowen boosted their price objective on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. Finally, Wells Fargo & Company upped their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $185.67.
Get Our Latest Stock Report on BDX
Becton, Dickinson and Company Profile
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Featured Articles
- Five stocks we like better than Becton, Dickinson and Company
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
